Abstract
Background: Renal cell carcinoma (RCC) is one of the most common diseases with limited treatment options. A better understanding of this disease and treatment has been hindered by a lack of representative preclinical models.
Methods: We established tumor organoids, three-dimensional cultures from clinical RCC samples. RCC organoids were characterized by H&E staining,
immunohistochemical staining and whole-exome sequencing. Organoids were derived from patients treated with different drugs to test their responses to the drugs.
Results: H&E staining, immunohistochemical staining and whole-exome sequencing revealed that RCC organoids recapitulated the histological feature and transcriptional profile of the parent tumor. Using the RCC organoid model, we found that RCC organoids exhibited differential responses to sunitinib, pazopanib, Cabozantinib, Lenvatinib + Everolimus, and MK6482 + Sunitinib treatment.
Conclusions: Our research suggests that organoids may become a favorable model for precise drug use in RCC.